INFLIXIMAB DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE IN CLINICAL REMISSION IS SAFE AND WELL TOLERATED

被引：0
|
作者：
Allegretti, Jessica R.
McClure, Emma L.
Marcus, Jenna
Norton, Beth Ann
Hamilton, Matthew
Winter, Rachel
De Silva, Punyanganie
Friedman, Sonia
Korzenik, Joshua R.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1874
引用
收藏
页码：S461 / S461
页数：1
相关论文
共 50 条
  • [1] Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated
    Allegretti, Jessica R.
    Canakis, Andrew
    McClure, Emma
    Marcus, Jenna
    Norton, Beth-Ann
    Hamilton, Matthew J.
    Winter, Rachel W.
    De Silva, Punyanganie S.
    Friedman, Sonia
    Korzenik, Joshua R.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 2031 - 2033
  • [2] Rational Infliximab De-Escalation in Crohn's Patients in Remission Using Infliximab Levels
    Allegretti, Jessica R.
    Carrellas, Madeline
    Hamilton, Matthew
    Friedman, Sonia
    Korzenik, Joshua R.
    GASTROENTEROLOGY, 2016, 150 (04) : S421 - S421
  • [3] De-Escalation of Therapy Is Not Cost-Effective in Patients With Crohn's Disease in Clinical Remission on Combination Therapy With Infliximab and Azathioprine
    Syal, Gaurav
    Almario, Christopher
    Melmed, Gil Y.
    Spiegel, Brennan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S349 - S349
  • [4] TREATMENT DE-ESCALATION IN CROHN'S DISEASE PATIENTS IN REMISSION UNDER INFLIXIMAB AND IMMUNOSUPPRESSANT THERAPY: THE SPARE TRIAL
    Louis, Edouard
    Resche-Rigon, Matthieu
    Laharie, David
    Ding, Nik
    Irving, Peter
    Lamb, Christopher
    Pollok, Richard
    Colombel, Jean-Frederic
    Hertervig, Erik
    Satsangi, Jack
    GUT, 2022, 71 : A27 - A27
  • [5] Accelerated infliximab infusions are safe and well tolerated in the treatment of Crohn's disease
    Fairclough, A
    Emery, P
    Heatley, RV
    Everett, SM
    Chalmers, DM
    Axon, AT
    Hamlin, PJ
    GUT, 2006, 55 : A80 - A81
  • [6] Treatment de-escalation in Crohn's disease
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 290 - 290
  • [7] Treatment de-escalation in Crohn's disease
    McShane, Cathy
    Kevans, David
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (05): : 401 - 401
  • [8] Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study
    Attar, Alain
    Duru, Gerard
    Roblin, Xavier
    Savarieau, Bernard
    Brunel, Pierre
    Lamure, Michel
    Peyrin-Biroulet, Laurent
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (01) : 112 - 119
  • [9] FACTORS ASSOCIATED WITH BIOLOGIC TREATMENT DE-ESCALATION IN PATIENTS WITH CROHN'S DISEASE
    Lien, P. W.
    Lee, T. A.
    VALUE IN HEALTH, 2024, 27 (06) : S38 - S38
  • [10] Appropriateness of De-Escalation of Medical Therapy in Crohn's Disease Patients Who Are in Deep Remission: A RAND Panel Approach
    Sparrow, Miles
    Melmed, Gil Y.
    Devlin, Shane
    Kozuch, Patricia
    Raffals, Laura
    Loftus, Edward V., Jr.
    Rubin, David T.
    Spiegel, Brennan M.
    Baidoo, Leonard
    Bressler, Brian
    Cheifetz, Adam
    Irving, Peter
    Jones, Jennifer
    Kaplan, Gilaad
    Velayos, Fernando
    Siegel, Corey A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S334 - S334
12345